SCHEMBL5541104

SCHEMBL5541104

CCOC(=O)c1c(O)c2ncc(Cc3ccc(F)cc3)cc2n(C2CC2)c1=O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE3B Q13370 1/20 0.40
PDE3A Q14432 1/20 0.40
KDM4E B2RXH2 6/20 0.39
MAPT P10636 2/20 0.39
PKM P14618 1/20 0.39
GRK6 P43250 1/20 0.38
ALDH1A1 P00352 5/20 0.38
ALOX5 P09917 1/20 0.38
MEN1 O00255 2/20 0.37
LMNA P02545 2/20 0.37
HPGD P15428 2/20 0.37
KMT2A Q03164 2/20 0.37
ALOX12 P18054 1/20 0.37
CCR6 P51684 1/20 0.37
HKDC1 Q2TB90 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
KDM4C Q9H3R0 1/20 0.37
RECQL P46063 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
TLR2 O60603 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5546784 0.86 TLR2 (0.42) ALDH1A1MEN1KMT2ATLR2
SCHEMBL4714636 0.86 ALDH1A1 (0.51) PDE3BPDE3AKDM4EMAPTPKM
SCHEMBL5545287 0.85 KDM4E (0.52) PDE3BPDE3AKDM4EMAPTPKM
SCHEMBL4761513 0.84 RECQL (0.49) PDE3BPDE3AKDM4EMAPTPKM
SCHEMBL5545789 0.82 TLR2 (0.42) ALDH1A1MEN1KMT2ASMN1; SMN2TLR2
SCHEMBL5547035 0.82 GRIN2B (0.45) KDM4EMAPTNPSR1
SCHEMBL5538837 0.82 KDM4E (0.41) PDE3BPDE3AKDM4EMAPTPKM
SCHEMBL5545776 0.82 KDM4E (0.41) PDE3BPDE3AKDM4EMAPTPKM
SCHEMBL5545282 0.82 KDM4E (0.55) PDE3BPDE3AKDM4EMAPTPKM
SCHEMBL5545582 0.82 KDM4E (0.41) PDE3BPDE3AKDM4EMAPTPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150225399-A1 HIV INTEGRASE INHIBITORS VIIV HEALTHCARE CO (US) 2015-08-13 US disclosed
US-20140256713-A1 2-OXONAPHTHYRIDINE-3-CARBOXAMIDES HIV INTEGRASE INHIBITORS SHIONOGI & CO., LTD. (JP) 2014-09-11 US disclosed
EP-1720856-B1 HIV INTEGRASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2013-08-14 EP disclosed
US-20070124152-A1 Hiv Integrase Inhibitors GLAXOSMITHKLINE LLC 2007-05-31 US disclosed
EP-1720856-A2 HIV INTEGRASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2006-11-15 EP disclosed
WO-2005077050-A2 HIV INTEGRASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2005-08-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140256713-A1 2-OXONAPHTHYRIDINE-3-CARBOXAMIDES HIV INTEGRASE INHIBITORS BCDIN3D, DUT, SAMHD1 PDE3B 3560/4885PDE3A 3339/4885KDM4E 1268/4885
US-20150225399-A1 HIV INTEGRASE INHIBITORS ING2, API5, SAMHD1 PDE3B 3316/4885PDE3A 3100/4885KDM4E 1255/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.